Translational Neuroscience Optimization of GlyT1 Inhibitor
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, randomized, double-blind, placebo-controlled, cross-over POC study of
stable patients with Schizophrenia or Schizoaffective disorder. The primary objective of this
study is to test the efficacy of treatment with one of two does of a glycine transporter
inhibitor (GlyT1I) combined with cognitive remediation to enhavce cognitive function.
Subjects will be randomized to one of two doses of the glycine transporter inhibitor (GlyT1I)
and placebo twice daily in addition to their antipsychotic medication for 2 treatment
periods, each lasting a minimum of 5 weeks. Treatment periods will be separated by a washout
period lasting approximately 3 weeks.